Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ShionogiFRA:SH0 -0.34%83 EV-to-EBIT is 8.81 as of Aug. 08, 2026, which is 7% below its 10-year median of 9.49. GuruFocus rates FRA:SH0 with a GF Score™ of 83/100 and a GF Value™ of €16.79 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 686 Drug Manufacturers companies, Shionogi ranks better than 75.22% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Shionogi's Enterprise Value for the quarter that ended in Jun. 2026 was €12,728 Mil.
Shionogi's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,530 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shionogi EV-to-EBIT Related Terms
Shionogi EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Shionogi's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shionogi's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shionogi EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shionogi's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Shionogi's EV-to-EBIT falls into.
Shionogi's current Enterprise Value is €13,485 Mil.
Shionogi's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,530 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shionogi (FRA:SH0) has a EV-to-EBIT of 8.81 as of Aug. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shionogi and its competitors. This is near median its historical median of 9.49. Over the past decade, Shionogi's EV-to-EBIT has ranged from 4.86 to 20.67. According to the industry distribution chart, Shionogi ranks #170 out of 686 companies in the Drug Manufacturers industry, placing it in the top 24.8%.
Is Shionogi's EV-to-EBIT too high?
Shionogi's current EV-to-EBIT of 8.81 is near median its 10-year median of 9.49. Over the past 10 years, this metric has ranged from a low of 4.86 to a high of 20.67. The Drug Manufacturers industry median EV-to-EBIT is 15.73. Shionogi's value of 8.81 is 44% below this industry median. Based on the distribution chart, Shionogi ranks #170 out of 686 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Shionogi has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shionogi's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shionogi ranks #170 out of 686 companies for EV-to-EBIT. This places Shionogi in the top 25% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.73. Shionogi's value of 8.81 is 44% below this benchmark. Historically, Shionogi's own EV-to-EBIT has ranged from 4.86 to 20.67 over the past decade. While the company's 10-year median is 9.49 vs. the industry median of 15.73, Shionogi has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.73, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shionogi's current EV-to-EBIT of 8.81 is 44% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Shionogi and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shionogi's current EV-to-EBIT is 8.81, which is near median its own 10-year median of 9.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shionogi stock overvalued right now?
Based on GuruFocus' analysis, Shionogi (FRA:SH0) is currently considered Modestly Undervalued. The stock's GF Value™ is €16.79, compared to a current price of €14.73 — trading 12.3% below its estimated fair value. The current EV-to-EBIT is 8.81, which is near median its 10-year median of 9.49 and 44% below the Drug Manufacturers industry median of 15.73. Shionogi's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Shionogi (FRA:SH0), the current EV-to-EBIT is 8.81 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shionogi (FRA:SH0) Overvalued in 2026?
Based on GuruFocus' analysis, Shionogi stock appears to be undervalued.
The current stock price of €14.73 is trading 12.3% below its estimated GF Value™ of €16.79.
GuruFocus considers Shionogi to be Modestly Undervalued.
Key valuation signals for FRA:SH0:
EV-to-EBIT: 8.81 (near median its 10-year median of 9.49)
GF Value™: €16.79 vs. price of €14.73 (12.3% below fair value)
Industry Position: 44% below the Drug Manufacturers median (#170 of 686)
No single metric tells the full story. See the FRA:SH0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shionogi & Co Ltd is a specialty and generic drug manufacturing company. The company focuses on the manufacturing and distribution of pharmaceuticals, diagnostic reagents, and medical devices. The company engages in manufacturing, formulation, packaging, and analysis as part of its commercialization research that spans late-stage drug discovery through commercial production. It provides products and services in Japan, Europe, North America, and other regions.
83GF Score
Get the complete analysis for FRA:SH0
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:SH0 has been successfully added to your 
